HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: JOE-08-0354v1 199/3/399    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caricilli, A. Articles by Saad, M. Search for Related Content PubMed PubMed Citation Articles by Caricilli, A. Articles by Saad, M.

A Caricilli, Internal Medicine, State University of Campinas, Campinas, Brazil
P Nascimento, Internal Medicine, State University of Campinas, Campinas, Brazil
J Pauli, Internal Medicine, State University of Campinas, Campinas, Brazil
D Tsukumo, Internal Medicine, State University of Campinas, Campinas, Brazil
L Velloso, Internal Medicine, State University of Campinas, Campinas, Brazil
J Carvalheira, Internal Medicine, State University of Campinas, Campinas, Brazil
M Saad, Internal Medicine, State University of Campinas, Campinas, Brazil

Correspondence: Andrea Caricilli, Email: caricilli{at}gmail.com

Abstract

The aims of the present study were to investigate the expression of TLR2 in muscle and white adipose tissue (WAT) of diet-induced obesity (DIO) mice and also the effects of its inhibition, by the use of TLR2 antisense oligonucleotide (ASON) on insulin sensitivity and signaling. Expression of TLR2 was increased in muscle and WAT of DIO mice, compared to those that received standard chow. Inhibition of TLR2 in DIO mice, by TLR2 ASON, improved insulin sensitivity and insulin signaling in muscle and WAT. In addition, data show that the inhibition of TLR2 expression prevents activation of IKKβ, JNK and serine phosphorylation of IRS-1 in DIO mice, suggesting that TLR2 is a key modulator of the cross-talk between inflammatory and metabolic pathways. We, therefore, suggest that a selective interference with TLR2 presents an attractive opportunity for the treatment of insulin resistance in obesity and type 2 diabetes.

This article has been cited by other articles:

				L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer Pharmacol. Rev., June 1, 2009; 61(2): 177 - 197. [Abstract] [Full Text] [PDF]